Albany Molecular Research, Inc. (AMRI) has selected a compound from its proprietary oncology research program for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) to the FDA in 2007. AMRI’s drug candidate is a novel analog of an established class of tubulin inhibitors, which kill cancer cells by preventing cell mitosis. In preclinical disease models, AMRI’s compound showed greater efficacy than marketed members of this class. ...